Gastroesophageal reflux disease (GERD) is the most common upper gastrointestinal (GI) disorder in the United States, defined as symptoms or lesions caused by the reflux of gastric contents into the esophagus. manage.

Patients who continue to have symptoms despite PPI therapy are considered to have refractory GERD, usually defined as the persistence of typical symptoms unresponsive to steady doses of PPIs twice daily. days for at least 12 weeks of treatment. Up to 30% of GERD patients have treatment-resistant GERD.

Patients who continue to have symptoms despite PPI therapy are considered to have refractory GERD, usually defined as the persistence of typical symptoms unresponsive to steady doses of PPIs twice daily. days for at least 12 weeks of treatment. Up to 30% of GERD patients have treatment-resistant GERD.

Patients who continue to have symptoms despite PPI therapy are considered to have refractory GERD, usually defined as the persistence of typical symptoms unresponsive to steady doses of PPIs twice daily. days for at least 12 weeks of treatment. Up to 30% of GERD patients have treatment-resistant GERD.